Comparative Study of Serum Homocysteine Level of Healthy Fertile Women and Patients with Recurrent Abortion

Document Type : Original Article

Authors

1 Associate Professor of Obstetrics and Gynecology, Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Professor of Obstetrics and Gynecology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 MD., Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 B.Sc. in Midwifery, Imam Hossein Hospital, Tehran, Iran

Abstract

Introduction: Recurrent abortion is a serious problem of obstetrics due to many different causes. Since homocysteine has important role in the embryonal implantation and growth, We did a comparative study of serum levels of homocysteine in patients with recurrent abortion and healthy fertile women.
Methods: This descriptive and prospective study enrolled 60 nonpregnant women in 15-40 years of age who referred to obstetric clinic of Imam Hossein hospital in Tehran in 2007-2008 periods. Reproductive age was enrolled in this study. 30 women had history of recurrent abortion. Genetic, anatomical. Hormonal and immunological factors as the cause of abortion resulted in exclusion of the patients .30 women with normal fertility history were selected as control group. The two groups were the same in other variables. The fasting serum homocysteine level was obtained in the patients with recurrent abortions (study group) and women in the control group. Data analysis was done by SPSS (13 version) and P value<0.05 was considered meaningful.
Results: The mean age was 29.9±7.5 and 30.1±5.3 in the study and control group respectively and there was no significant difference. The parity was 2.8±1.3 in the control group and 4.6±1.2 in the study group while the number of abortion in the study group was 4.13±1.02 and none in the control group. Although only higher than normal levels of homocysteine was seen in 3 patients of the recurrent abortion group, the mean level of serum homocysteine was significantly higher in the study group than the normal fertile women 10.05±3.8 µmol/L versus 8.2±2.3 µmol/L respectively).
Conclusion: The vascular effects of hyperhomocysteinemia results in impaired implantation and growth of embryo ending in recurrent abortions. So checking the level of serum homocysteine is recommended in the evaluation of recurrent abortions and in case of increase prophylactic measures could be implemented.

Keywords

References

1. Kim NK, Choi YK, Kang  MS, Choi DH, Cha SH, An MO, et al. Influence of combined  methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER)
polymorphisms to  plasma  homocysteine levels in Korean patients with recurrent spontaneous  abortion. Thromb Res 2006;117(6):653­8. 2. Coulam, CB., Clark, DA., Beer, A.E, Kutteh WH, Silver R, Kwak J. Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Clinical Guideline Recommendation  Committee for Diagnosis and Treatment of Recurrent Spontaneous Abortion. Am J Reprod Immunol
1997 Aug;38(2):57–74. 3. Wouters MG, Boers GH, Blom HJ, Trijbels FJ, Thomas CM, Borm GF, et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993 Nov;60(5):820­5. 4. Coumans AB, Huijgens PC, Jakobs C, Schats R, de Vries JI, van Pampus MG, et al. Haemostatic and  metabolic  abnormalities in women with unexplained recurrent abortion. Hum Reprod 1999 
Jan;14(1):211–4. 5. Parle­McDermott A, Pangilinan.F, Mills.JL, Signore CC, Molloy AM, Cotter A, et al. A
polymorphism in the MTHFD1 gene increases a mother’s risk of having  an unexplained second 
trimester pregnancy loss. Mol Hum Reprod 2005 Jul;11(7):477–80. 6. Mtiraoui N, Zammiti W, Ghazouani L,  Braham NJ, Saidi S, Finan RR, et al. Methylenetetrahydrofolate reductase C677T and A1298C polymorphism and changes in homocysteine  concentrations in women with idiopathic  recurrent pregnancy losses. Reproduction  2006 
Feb;131(2):395­401. 7. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations  about total homocysteine determinations: an expert opinion. Clin Chem 2004 Jan;50(1):3­32 
8. Ronnenberg AG, Venners SA, Xu X, Chen C, Wang L, Guang W, et al. Preconception B­vitamin and 
homocysteine status, conception, and early pregnancy loss. Am J Epidemiol 2007 Aug 1;166(3):304­ 12. 9. Bonnette RE, Caudill MA, Boddie AM, Hutson AD, Kauwell GP, Bailey LB. Plasma homocysteine  concentrations in pregnant and non­pregnant women with controlled folate intake. Obstet Gynecol
1998 Aug;92(2):167–70. 10. Gris JC, Perneger TV, Quere I, Mercier E, Fabbro­Peray P, Lavigne­Lissald G, et al. Antiphospholipid/antiprotein antibodies, hemostasis­related autoantibodies,and plasma homocysteine  as risk factors for a first early pregnancy loss: a matched case­control study. Blood 2003 
Nov;102(10):3504­13. 11. Kumar KS, Govindaiah V, Naushad SE, Devi RR, Jyothy A. Plasma homocysteine levels correlated 
to  interactions between folate status and methylene tetrahydrofolate reductase gene mutation in  women with unexplained recurrent pregnancy loss. J Obstet Gynaecol 2003 Jan;23(1):55­8. 12. Ray JG and Laskin CA. Folic  acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre­eclampsia and spontaneous pregnancy loss: a systematic  review. Placenta 1999 
Sep;20(7):519–29. 13. Nelen WL, Steegers EA, Eskes TK, Blom HJ. Genetic risk factor for unexplained recurrent early 
pregnancy loss. Lancet 1997 Sep 20;350(9081):861. 14. Cotter AM, Molloy AM, Scott JM and Daly SF . Elevated plasma homocysteine in early pregnancy: a 
risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001 Oct;185(4):781–  785. 15. Calle M, Usandizaga R, Sancha M, Magdaleno F, Herranz A, Cabrillo E. Homocysteine, folic acid  and B­group vitamins in obstetrics and gynaecology. Obstet Gynecol Reprod Biol 2003 Apr 25;107(2):125–34.
 
16. Hogg  BB, Tamura T, Johnston KE, Dubard MB, Goldenberg  RL. Second­trimester plasma  homocysteine levels and pregnancy­induced hypertension, preeclampsia, and intrauterine growth 
restriction. Am J Obstet Gynecol 2000 Oct;183(4):805–9. 17. Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez­Casal M, Toh CH. Postnatal screening  for
thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001 May;97(5Pt
1):753–9. 18. Hietala R, Turpeinen U and Laatikainen T. Serum homocysteine at 16 weeks and subsequent
preeclampsia. Obstet Gynecol.2001 Apr;97(4):527–9. 19. Bergant AM, Reinstadler K., Moncayo  HE. Spontaneous abortion and psychosomatics. A
prospective study on the impact of psychological factors as a cause for recurrent spontaneous  abortion. Hum Reprod 1997 May;12(5):1106–10. 20. Gindler J, Li Z, Berry RJ, Zheng J, Correa A, Sun X, et al. Folic acid supplements during pregnancy  and risk of miscarriage. Lancet 2001 Sep 8;358(9284):796–800. 21. Nelen WL, Bulten J, Steegers EA, Blom HJ, Hanselaar AG, Eskes TK. Maternal homocysteine and 
chorionic vascularization in recurrent early pregnancy loss. Hum Reprod 2000 Apr;15(4):954–60. 22. Unander AM, Norberg R, Hahn L, Arfors L. Anticardiolipin antibodies and complement in ninety­ nine women with habitual abortion. Am J Obstet Gynaecol 1987 Jan;156(1):114–9. 23. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate 
reductase gene is a genetic risk for cardiovascular disease. Am J Hum Gen 1996 Jan;58(1):35–41. 24. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease  and thrombosis. Thromb Res 1993 Sep 1;71(5):337–59. 25. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, et al. Prevention of neural­tube defects with 
folic acid in China. China­U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J 
Med 1999 Nov 11;341(20):1485–90. 26. Steegers­Theunissen RP, Boers GH, Blom HJ, Trijbels FJ, Eskes TK. Hyperhomocysteinaemia and 
recurrent spontaneous abortion or abruptio placentae. Lancet 1992 May 2;339(8801):1122–3. 27. Rajkovic A, Catalano PM, Malinow MR. Elevated homocysteine levels with preeclampsia. Obstet
Gynecol 1997 Aug;90(2):168 –71. 28. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers GH, Eskes TK. Methylenetetrahydrofolate 
reductase polymorphism affects the change in homocysteine and folate concentrations resulting from
low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr 1998 
Aug;128(8):1336–41. 29. Ray JG, Laskin CA. Folic  acid and homocyst(e)ine metabolic  defects and the risk of placental abruption, pre­eclampsia and spontaneous pregnancy loss: A systematic  review. Placenta 1999 
Sep;20(7):519 –29. 30. Nelen WL, Steegers EA, Eskes TK, Blom HJ. Genetic risk factor for unexplained recurrent early 
pregnancy loss. Lancet 1997 Sep 20;350(9081:861. 31. Quere I, Bellet H, Hoffet M, Janbon C, Mares P, Gris JC. A woman with five consecutive fetal
deaths: case report and retrospective analysis of hyperhomocysteinemia prevalence in 100 consecutive  women with recurrent miscarriages. Fertil Steril 1998 Jan;69(1):152–4.

Files

Share

How to cite

Statistics